Re: Singh et  al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785)

We read with interest the article by Singh et  al1 that presented separate and pooled data from 2 large prospective (studies 1 and 2), randomized, parallel, phase III clinical trials demonstrating that nepafenac 0.3% once daily reduced the risk of macular edema (ME) after cataract surgery in patients with diabetic retinopathy (DR). The study h as several notable strengths including its large size (>600 eyes enrolled in each study), rigorous design, and use of an objective definition of ME (30% change from baseline).
Source: Ophthalmology - Category: Opthalmology Authors: Tags: Correspondence Source Type: research